Core Points - Yunnan Biotech Pharmaceutical Co., Ltd. (referred to as "Biotech") announced that the Yunnan Provincial High People's Court upheld the original ruling, sentencing former actual controller Lin Yanhe to three years in prison and a fine of 5 million yuan, while former CFO He Yuan received a sentence of one and a half years and a fine of 2 million yuan [1] - The case involved Lin Yanhe and He Yuan misappropriating company funds for personal financial needs, leading to administrative penalties from the China Securities Regulatory Commission (CSRC) and subsequent criminal charges [1][2] - The CSRC has been actively enforcing strict regulations against financial misconduct, emphasizing the protection of small investors and the integrity of innovative small and medium-sized enterprises [2] Company Overview - Biotech was established in 1999 and focuses on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system [1] - The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [1] Legal Proceedings - The case against Lin Yanhe and He Yuan for breaching fiduciary duties was heard in Kunming Intermediate People's Court, resulting in a conviction and financial penalties, with the court ordering the return of misappropriated funds to Biotech [2] - The Yunnan Securities Regulatory Bureau initiated an investigation into the misconduct, leading to significant administrative penalties and a referral for criminal prosecution [1][2]

Core Viewpoint - Yunnan Biological Valley Pharmaceutical Co., Ltd. has faced legal consequences for financial misconduct involving its former actual controller and financial director, highlighting the regulatory environment's strict stance against such violations [2][3]. Company Summary - Yunnan Biological Valley was established in 1999, focusing on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system drugs. The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [2]. - The former actual controller, Lin Yanhua, and the former financial director, He Yuan, were found guilty of misappropriating company funds for personal financial needs, leading to their convictions and sentences [2][3]. Regulatory Actions - In May 2022, the Yunnan Securities Regulatory Bureau initiated an investigation into the illegal activities, resulting in administrative penalties of 5 million yuan for Lin Yanhua and 2 million yuan for He Yuan, along with market entry bans [3]. - The case reflects the China Securities Regulatory Commission's commitment to combating financial misconduct and protecting the rights of small investors, emphasizing a zero-tolerance policy towards fund misappropriation [3].

生物谷（920266）12月3日大宗交易平台出现一笔成交，成交量10.00万股，成交金额70.00万元，大宗交 易成交价为7.00元，相对今日收盘价折价26.32%。该笔交易的买方营业部为中国银河证券股份有限公司 佛山绿景一路证券营业部，卖方营业部为国新证券股份有限公司昆明拓东路证券营业部。 据天眼查APP显示，云南生物谷药业股份有限公司成立于1999年06月13日，注册资本12400.0007万人民 币。（数据宝） 12月3日生物谷大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | | | | | 中国银河证券股份有限公 | 国新证券股份有限公 | | 10.00 | 70.00 | 7.00 | -26.32 | 司佛山绿景一路证券营业 | 司昆明拓东路证券营 | | | | | | 部 | 业部 | （文章来源：证券时报网） 进一步统计，近1个月内该股累计发生2笔大宗交易，合计成交金额为190.0 ...

证券日报网讯12月2日晚间，生物谷发布公告称，截至2025年11月28日，公司已通过集中竞价交易方式 累计出售回购股份527，630股，占公司总股本的比例为0.43%，成交总额为5，098，846.83元(未扣除交 易费用、税金)，成交最高价为10.11元/股，最低价为9.34元/股，均价为9.66元/股。 ...

Core Viewpoint - A block trade of 150,000 shares of Yunnan Biovalley Pharmaceutical Co., Ltd. was executed on November 5, with a transaction price of 8.00 yuan, representing a discount of 25.02% compared to the closing price of 10.67 yuan on the same day [2] Group 1: Trade Details - The transaction volume was 150,000 shares, with a total transaction value of 1.2 million yuan [2] - The buyer was Guotou Securities Co., Ltd. Meizhou Fengshun Securities Branch, while the seller was Guoxin Securities Co., Ltd. Kunming Tuodong Road Securities Branch [2] - The closing price of Yunnan Biovalley on November 5 was 10.67 yuan, reflecting an increase of 1.43% with a turnover rate of 2.50% and a total trading volume of 21.45 million yuan for the day [2] Group 2: Company Background - Yunnan Biovalley Pharmaceutical Co., Ltd. was established on June 13, 1999, with a registered capital of 1.24 billion yuan [2]

Core Insights - The article highlights the development of a billion-level "Northern Bio Valley" in Dezhou, focusing on the growth of the biotechnology industry through collaboration and innovation [1][2][4] Industry Overview - Dezhou is concentrating on five key areas within the biotechnology sector: biomanufacturing, biomedicine, bio-agriculture, biomedical engineering, and biomass energy, aiming for high-end, clustered, and international development [2][3] - The city has established a clear framework for its biotechnology industry, with 153 enterprises in the sector and projected revenue of 40.4 billion yuan in 2024 [2] Innovation and Collaboration - Innovation is identified as the core driver for overcoming challenges and seizing development opportunities, supported by numerous national and provincial innovation platforms [3] - Dezhou has established long-term collaborations with over 40 universities and research institutions, holding nearly 300 patents related to biopreparation [3] Regional Development - Different regions within Dezhou are focusing on specific areas of biotechnology, such as biomanufacturing in Yucheng and medical devices in Qihe, creating a diverse and collaborative development landscape [4] - The city has mechanisms in place for regular roadshows and result transformation, targeting investors, entrepreneurs, and industry experts to facilitate efficient connections among technology, capital, market, and policy [4] Future Outlook - Dezhou aims to target cutting-edge fields such as synthetic biology, gene cell therapy, and AI pharmaceuticals, with plans to establish high-level innovation platforms and pilot bases [4] - The city is committed to enhancing its industrial cluster development, optimizing its industrial layout, and attracting leading enterprises and major projects to achieve the goal of becoming a billion-level "Northern Bio Valley" [4]

Core Insights - The article discusses the development of a billion-level "Northern Bio Valley" in Dezhou, focusing on the growth and innovation in the biotechnology industry [1][3][6] Industry Overview - Dezhou is concentrating on five key areas within the biotechnology sector: biomanufacturing, biopharmaceuticals, bio-agriculture, biomedical engineering, and biomass energy [3] - The city has established a clear layout and strong innovation initiatives to promote high-end, clustered, and international development of the industry [3] Current Developments - The biomanufacturing industry in Dezhou has seen significant growth, with 153 enterprises in the sector and projected revenue of 40.4 billion yuan in 2024 [3] - Eight companies in the biotechnology sector have achieved over 1 billion yuan in output value, while 41 companies have surpassed 100 million yuan [3] Innovation and Collaboration - Innovation is identified as the core driver for overcoming challenges and seizing development opportunities in the biotechnology industry [4] - Dezhou has established numerous national and provincial innovation platforms and maintains long-term collaborations with over 40 universities and research institutions [4] Product Development - Companies like Baolingbao Biological Co., Ltd. are developing new products such as erythritol, with a production capacity of 30,000 tons per year, and exporting to over 70 countries [4] Strategic Initiatives - Dezhou is implementing mechanisms for regular roadshows and results transformation to connect investors, entrepreneurs, and industry experts [5] - The city is also exploring the establishment of a specialized fund for the biotechnology industry and has formed an association for high-quality development in the sector [5] Future Outlook - Dezhou aims to focus on cutting-edge areas such as synthetic biology, gene cell therapy, and AI pharmaceuticals, while continuing to optimize its industrial layout and attract leading enterprises [6]

Core Viewpoint - The company Biotech Valley (920266.BJ) announced the sale of 762,514 shares that were repurchased in 2022, which represents 0.61% of its total share capital. The proceeds from this sale will be used to supplement the company's working capital [1]. Group 1 - The company will hold its fifth board meeting on October 20, 2025, to review the proposal for selling the repurchased shares [1]. - The sale period for the repurchased shares will begin 15 trading days after the announcement and will last until December 8, 2025, with restrictions during any periods prohibited by the China Securities Regulatory Commission and the Beijing Stock Exchange [1]. - The selling price of the shares will be determined based on the market price at the time of sale, with a stipulation that the declared price cannot be lower than the daily trading limit [1]. Group 2 - Biotech Valley was listed on the Beijing Stock Exchange on November 15, 2021, becoming the first company from Yunnan to be listed there [3]. - The company previously went public on July 27, 2020, on the National Equities Exchange and Quotations (NEEQ) with an issuance of 6.849 million shares at a price of 13.99 yuan per share, raising a total of approximately 95.82 million yuan [2].

云南生物谷药业股份有限公司 章 程 二〇二五年 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《北京证券交易所股票上市规则》 和其他有关规定，制定本章程。 第二条 云南生物谷药业股份有限公司系依照《公司法》和其他有关规定成立 的股份有限公司（以下简称"公司"）。 公司系由云南生物谷灯盏花药业有限公司（以下简称"有限公司"）整体变 更，并由有限公司原股东以发起设立方式设立；在云南省昆明市市场监督管理局 （原云南省昆明市工商行政管理局）注册登记，取得营业执照，统一社会信用代 码为 915301007134092367。 第三条 公司于 2020 年 6 月 21 日经全国中小企业股份转让系统有限责任公 司（以下简称"全国股转公司"）审核同意，于 2020 年 6 月 24 日经中国证券监 督管理委员会（以下简称"中国证监会"）核准，首次向不特定合格投资者公 开发行人民币普通股 6,849,000 股，于 2020 年 7 月 27 日在全国中小企业股份转 让系统（以下简 ...

（一）会议召开情况 1.会议召开时间：2025 年 9 月 28 日 2.会议召开地点：公司会议室 3.会议召开方式：现场召开 证券代码：833266 证券简称：生物谷 公告编号：2025-108 云南生物谷药业股份有限公司 2025 年第一次职工代表大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 4.发出职工代表大会会议通知的时间和方式：2025 年 9 月 26 日 以通讯方式发出 5.会议主持人：旃源 6.召开情况合法、合规、合章程性说明： 本次职工代表大会的召集、召开及表决程序符合《公司法》和《公 司章程》的相关规定，所作决议合法有效。 （二）会议出席情况 会议应出席职工代表 47 人，实际出席职工代表 38 人。 二、议案审议情况 （一）审议通过《关于选举公司第五届董事会职工代表董事的议案》 1.议案内容： 为进一步完善公司治理结构，根据《公司法》《上市公司章程指 引》《北京证券交易所股票上市规则》《公司章程》等相关规定，结 合公司实际情况，公司取消监事会 ...